Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease. by Natoli, C. et al.
Br. J. Cancer (1993), 67, 564-567 © Macmillan Press Ltd., 1993~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Dynamic test with recombinant interferon-alpha-2b: effect on 90K and
other tumour-associated antigens in cancer patients without evidence of
disease
C. Natoli', C. Garufi', N. Tinaril, M. D'Egidiol, G. Lesti2, L.A. Gaspari3, R. Visini3 &
S. Iacobellil
'Cattedra di Oncologia Medica; 2Cattedra di Clinica Chirurgica; 3Cattedra di Semeiotica Chirurgica, Universita 'G. D'Annunzio',
66100 Chieti, Italy.
Summary We have previously shown that a short course of recombinant interferon-alpha-2b (rIFN-alpha-2b)
(3 million units day for 5 days) for patients with primary gynaecologic malignancies was able to increase the
circulating levels of a newly discovered tumour associated antigen, termed 90K. In this study, we have
investigated the effects of the same modality of administration of rIFN-alpha-2b in 62 patients with breast and
colorectal cancer whose primary tumour was surgically removed I month before and who were without
evidence of disease (NED) at the time of the study. A significant increase of 90K serum concentration was
already observed 24 h after the first r-IFN-alpha-2b injection and persisted throughout the investigational
period. The increase was more pronounced in patients with a basal 90K-negative than a 90K-positive assay.
Of 54 patients who started the test with a 90K negative assay, 17 (31%) shifted to a positive assay after
rIFN-alpha-2b. Twenty-eight of 62 (45%) patients exhibited a 90K value above the mean increment of the
whole population. The serum levels of CEA, CA-15-3, CA 19-9, and alpha-fetoprotein measured in the same
serum samples were not modified. After 2 years of follow-up, ten patients relapsed. Six of them showed a 90K
increase above the mean increment of the whole population. As with ovarian cancer, the increase of 90K
following r-IFN-alpha-2b administration might be of importance for the early detection of disease recurrence
in clinically NED breast and colon cancer patients.
Assay of circulating tumour associated antigens (TAAs) is a
common procedure in the management of cancer patients.
The important clinical application of TAAs is to monitor
disease activity and response to therapy. However, due to
poor sensitivity of currently employed assay procedures,
TAAs are of limited value for the detection of small residual
tumour or early recurrence after primary surgery. This in-
adequacy could be overcome by substance(s) able to
stimulate the synthesis and/or release ofTAAs by cancer cells
thereby facilitating tumour serodetection.
It is known that interferons (IFNs) may enhance the exp-
ression of TAAs in vitro on cultured cells (Attallah et al.,
1979; Liao et al., 1982; Greiner et al., 1984; Giacomini et al.,
1985; Greiner et al., 1986a; Guadagni et al., 1987; Boyer et
al., 1989; Marth et al., 1989; Guadagni et al., 1990) and in
vivo in nude mice bearing transplanted human tumours
(Greiner et al., 1986b; Rowlinson et al., 1986). Moreover, we
first reported (Iacobelli et al., 1988a) that the administration
of recombinant interferon alpha-2b (rIFN-alpha-2b) in
patients with breast cancer was able to augment the cir-
culating levels of a 90,000 daltons TAA, termed 90K. This
antigen which is identified by monoclonal antibody SP-2
(lacobelli et al., 1986), is secreted into the tissue culture fluid
of CG-5 human breast cancer cells and is found at increased
concentrations in the serum of patients with various malig-
nancies (Iacobelli et al., 1988b). More recently, Scambia et al.
(1990) showed that a short course of rIFN-alpha-2b
(3 x 106 U m-2 day for 3 days) increased 90K serum levels in
patients with primary gynaecologic tumours. Interestingly,
some patients who were 90K-negative before rIFN-alpha-2b
administration became 90K-positive after treatment, leading
to the suggestion that this dynamic stimulation with rIFN-
alpha-2b could be used to improve cancer serodetection.
The present study was undertaken to evaluate whether this
dynamic stimulation with rIFN-alpha-2b was able to increase
the serum levels of 90K and other TAAs in cancer patients
with no evidence of disease (NED) after surgery for breast
and colorectal carcinoma.
Materials and methods
Patients
Sera were obtained from 62 patients who underwent radical
surgery for primary tumour, 49 breast carcinomas, and 13
colorectal carcinomas between January and June 1990. All
patients included in the study were NED and out of therapy
at the time of the test. An informed consent was obtained
from each patient. Sera were stored at - 20'C until assayed.
Patients' follow-up was performed at regular intervals.
Dynamic test
The test consisted in the administration of rIFN-alpha-2b
(Intron A, Schering-Plough, Milan, Italy) at the dose of
3 x 106 U day intramuscularly for 3 consecutive days. Blood
samples were drawn daily for 5 days, the first three samples
being taken just before rIFN-alpha-2b administration. The
test was performed 30-45 days after surgery. This period of
time was chosen on the basis of previous data (lacobelli et
al., 1988b) showing that the antigen levels were in the normal
range within 1 month after surgery for primary breast cancer.
Similarly, in 38 patients with benign conditions (12 uterine
fibromatosis, seven benign breast disease, five thyroid
adenoma, five appendicitis, four inguinal hernia, three kidney
lithiasis, one pancreatitis, one pulmonary carcinoid) no
significant variations of 90K levels were observed after
surgery (unpublished results).
Assay of TAAs
Serum 90K was measured by a newly developed immuno-
radiometric assay (IRMA) which follows the general prin-
ciples as the previously reported ELISA (lacobelli et al.,
1988b). The IRMA uses polystyrene beads (6.5 mm, Precision
Plastic Balls, Chicago. III) coated with biotinylated Mab SP-2
as solid phase and ['25I]SP-2 as the labelled antibody (Suter et
al., 1988; Guesdon et al., 1979). Coated beads were treated
with an overcoating solution of bovine serum albumin
(2 mg ml-') for 1 h at room temperature, washed with water
and stored at room temperature until used. Beads treated in
this fashion were stable for at least 6 months. With each
assay, 200 tll of appropriately diluted serum samples or stan-
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dard were incubated with one SP-2-coated bead for 1 h at
37°C. After washing with distilled water, the beads were
incubated with 100 pl of ['25I1SP-2 (approximately 50,000
c.p.m.; specific activity 1O l.Ci lg- ) for one additional hour
at 37°C. Labelling of SP-2 was carried out by the chloramine-
T method (McConahey & Dixon, 1980). Beads were washed
with distilled water and counted in the gamma counter. The
amount of 90K in the sample was calculated by reference to
the amount present in standard preparation made of a pool
of sera from breast cancer patients and titered to contain 40,
20, 10, 5 arbitrary units (U) ml-'. One arbitrary unit corres-
ponds to approximately 100 ng of 90K as evaluated by
comparison of the results of IRMA with those of protein
determination of pure 90K preparations (unpublished re-
sults). The assay, developed in collaboration with Sorin
Biomedica (Saluggia, Italy), has inter- and intra-assay
coefficients of variation of 4%. The simultaneous assay of
120 sera from breast cancer patients using the IRMA and the
previously developed ELISA (lacobelli et al., 1988b) gave a
correlation coefficient of 0.91 (Kendall Q test; data not
shown). Mean 90K serum level by IRMA in 200 healthy
control subjects is 5.7 ± 2.6 U ml', a value of 11.0 U ml-'
(mean normal level plus two standard deviations) was
adopted as the cut-off limit for the normal range, and serum
levels higher than this value were considered as positive. 90K
concentration in serum did not depend on either sex, age or
blood group (Iacobelli et al., 1988b). Moreover, the levels of
90K remained stable during daily measurement over a period
of 10 consecutive days (unpublished results).
Serum CEA, CA 15-3, CA 19-9 and alpha-fetoprotein were
measured by commercially available immunoassays kits
(Sorin Biomedica, Saluggia, Italy). The coefficients or intra-
assay variation for CEA, CA 15-3, CA 19-9 and alpha-
fetoprotein were 7.5%, 6%, 5%, and 8%, respectively and
those for inter-assay variation 7.1%, 6.5%, 7.5%, and 5.9%,
respectively. Cut-off limits for normal ranges were as follows:
CEA, Sngml-'; CA 15-3, 30Uml-'; CA 19-9, 37Uml-',
alpha-fetoprotein, 15 ng ml- '.
Statistical analysis
A Student's t-test for paired data was used to evaluate the
modifications of TAAs during the 5 days of the test.
Results
Eight out of 62 (13%) patients had positive (>11 U ml-')
90K basal serum levels (7/49 breast carcinomas, 1/13 colorec-
tal carcinomas). This rate of 90K positivity in NED cancer
patients agrees with previous data (Iacobelli et al., 1988b).
The administration of rIFN-alpha-2b significantly (P<
0.001) increased 90K serum levels over the mean of pretreat-
ment values (Table I and Figure 1). The stimulatory effect
was already evident 24 h after the first rIFN-alpha-2b
administration and progressively increased throughout the
period of observation. Patients with breast and colorectal
cancer had similar pattern of response to rIFN-alpha-2b with
maximal 90K increase of 39% and 56%, respectively.
As Figure 2 shows, the increase of 90K was more pro-
nounced for patients who started the test with a negative
(<11 U ml-') assay than for those with a positive assay
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Figure 1 Effect of rIFN-alpha-2b on 90K serum levels in the
whole population (-) and in patients with breast (A), and
colorectal cancer (0). Each point represents mean 90K values for
each group of patients.
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Figure 2 Effect of rIFN-alpha-2b on 90K serum levels in the
whole population (-), in patients with basal 90K values less (0),
and greater (A) than 11 U ml-'. Values are expressed as per cent
of increase compared to basal (pre-treatment) values.
(51% vs 27%). Moreover 17 of the 54 (31%) 90K-negative
patients became 90K-positive after rIFN-alpha-2b with a
similar proportion among breast cancers (13/49, 26%) and
colorectal cancers (4/13, 31%). Considering that the mean
increment of 90K in the whole population is 40%, then 28/62
(45%) patients exhibited an antigen increment above this
value.
Neither CEA, nor CA 19-9, CA-15-3 or alpha-fetoprotein
showed significant modifications during the 5 days of the test
(Figure 3). No remarkable side effects due to rIFN-alpha-2b
administration were observed. Toxicity consisted of mild
fever, fatigue and weakness in some cases.
After 2 years of follow-up, three patients with colorectal
and seven with breast cancer relapsed. Among them, six
patients (two colorectal and four breast cancer) showed a
90K increase following rIFN-alpha-2b administration higher
than 40%, i.e. the mean 90K increment in the whole popula-
tion; one breast cancer patient shifted from a negative to a
positive value and two other breast cancer patients had very
elevated pretreatment 90K (101 U ml1' and 26.7 U ml-')
though their 90K values did not vary during the test. In the
remaining relapsing patient with colorectal cancer 90K did
not show any variation.
Table 1 90K levels (unitsml-') during the test in the whole patient population
Days 1 2 3 4 5
Mean 7.86 10.24a l0.89a 1l.OSa 10.34a
S.D. 7.11 7.47 7.54 8.40 8.24
Median 5.95 8.60 8.85 9.05 8.52
Range 1.65-42.05 2.41-49.34 2.57-43.75 2.82-54.74 2.17 ± 51.41
aP<0.001 vs basal values (day 1) by paired t-test.566 C. NATOLI et al.
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Figure 3 Effect of rIFN-alpha-2b on CA 15-3 (0), CA 19-9
(0), CEA (A) and alpha-fetoprotein (A) serum levels. Mean
values are represented.
Discussion
In a previous study (Scambia et al., 1990), it was demon-
strated that the preoperative administration of rIFN-alpha-
2b to patients with breast and gynaecologic cancer increased
the circulating levels of 90K. The work reported here shows
that the dynamic stimulation with rIFN-alpha-2b is also
effective in patients with colorectal and breast cancer who are
clinically NED after surgical removal of the primary tumour.
The significance of 90K rise in NED breast and colorectal
cancer patients induced by rINF-alpha-2b has not yet been
established. Cure rate in these patients is 50-60% (Berger et
al., 1988); some of these patients have micrometastatic
disease already at the time of the primary surgery (Berger et
al., 1988; Fisher & Turnbull, 1955). Although in the absence
of an adequate follow-up it is not possible to establish when
the dynamic test has to be considered as 'true positive', i.e.,
leading to augmented antigen expression in those patients
who will develop disease recurrence shortly after, two pos-
sibilities can be envisaged: either a shift from a negative
(below the cut-off value) to a positive assay or a given
increase of the antigen level irrespective of the basal value. In
our series of patients, approximately one of three of them
shifted from a negative to a positive 90K assay after rINF-
alpha-2b, whereas an augmentation of the antigen level
above the mean increment of the whole population (40%)
was seen in approximately one of two cases. Although the
number of relapsing patients is too small to allow any statis-
tical evaluation, it is meaningful that six out of ten of them
exhibited an increase of 90K levels over 40%, whereas none
but one shifted from a negative to a positive assay.
The stimulatory effect of rIFN-alpha-2b on 90K in our
patient population was more pronounced in antigen-negative
than in antigen-positive patients. As suggested for other
TAAs (Liao et al., 1982; Greiner et al., 1984), this may reflect
differences in sensitivity to rIFN-alpha-2b of genes and/or
cellular elements involved in 90K production which could
preferentially be stimulated when the constitutive 90K level is
low. This same situation could explain why we failed to
observe any increase of 90K after rIFN-alpha-2b in two
relapsing patients with very high 90K pretreatment serum
levels. If confirmed on a larger series, this could imply that
the dynamic test should be performed only on patients
exhibiting a negative 90K basal value.
Basal 90K levels were not modified by rIFN-alpha-2b in
non-cancer patients including 12 women with genital con-
dylomatosis (lacobelli et al., 1988a; Scambia et al., 1990) and
in eight patients with chronic viral-B hepatitis (unpublished
data). Although these control data were obtained from non-
operative patients, we have evidence that surgery per se does
not alter 90K levels (lacobelli et al., 1988b and Materials and
methods). That a 90K increase following rIFN-alpha-2b
administration in otherwise clinically NED patients may
identify subgroups at high risk of recurrence is further sug-
gested by the results of a recent study using the dynamic test
in a group of 26 patients with ovarian cancer (Scambia et al.,
1991). Despite all patients were in clinical complete remission
after surgery and chemotherapy, some of them exhibited a
significant rIFN-alpha-2b induced-increase of 90K serum
level that was accompanied by the presence of disease at
second-look surgery. More importantly, two of four patients
with no disease at second-look but with a marked enhance-
ment of 90K levels had disease recurrence 13 and 24 months
later, while none of 13 patients with a negative dynamic test
relapsed.
The mechanisms by which rIFN-alpha-2b increases 90K is
not known. The stimulatory effect on CG-5 cells in vitro
involves new protein synthesis and is dissectable from the
antiproliferative activity in terms of dose dependency
(lacobelli et al., 1988a). However, the overall response to
rIFN-alpha-2b in vivo may depend on other variables. First,
the amount of 90K constitutively expressed within the
stimulated tumour cells as discussed above. Second, the
presence in the cells of functionally active interferon recep-
tors as well as post-receptor mechanism(s). Third, the
number of occult cancer cells present in the patient at the
time of the test. In vitro data have shown that approximately
50,000 CG-5 human breast cancer cells are needed to release
enough 90K to be measured by the current assay procedure
and that about three times less cells are required when rIFN-
alpha-2b is added (lacobelli et al., 1988a). Therefore, assum-
ing that increased 90K after rIFN-alpha-2b in our patients
originates from enhanced production by occult cancer cells,
the sensitivity of the assay is augmented of approximately
three times. Finally, it is possible that the response to rIFN-
alpha-2b may be influenced by other factors such as the
degree of differentiation of individual cancer, or intrinsic
biological characteristics of the tumour as well as degrada-
tion rate of the 90K antigen.
The effect of rIFN-alpha-2b on 90K seems to have some
specificity since neither CEA, nor CA 15-3, CA 19-9 or
alpha-fetoprotein varied significantly during the 5 days of the
test. A recent report (O'Connell et al., 1989) has shown that
the administration of rIFN-gamma to patients with advanced
metastatic colorectal carcinoma can enhance the circulating
levels of CA 19-9 and to a lesser extent of CA 15-3. Similar
to our findings, the increase was seen within 24 h after drug
administration but it was independent of basal antigen level.
Further studies using different types of interferon as well as
optimal doses and timing of administration are required.
In conclusion, this serum test with rIFN-alpha-2b may be
indicative of disease recurrence in clinically NED cancer
patients. Its value in this setting is the focus of a large
prospective clinical trial now under way at the University of
Chieti Medical School.
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